SOE Grade	Study Design: No. Studies (N)	Study Limitations	Directness	Consistency	Precision	Reporting Bias	Other Issues	Findings
CNSDose								
Remission: Moderate	1 RCT, N=148[13]	Low	Direct	Unknown	Precise	None	None	Improved remission (HAM-D ≤ 7): 72% guided vs 28% usual care; RR 2.52 (95% CI 1.71 to 3.73)
Proportion taking sick leave: Low	1 RCT, N=148[13]	Low	Direct	Unknown	Imprecise	None	None	Proportion taking sick leave: Usual care=15% vs guided=4%; RR 1.13 (95% CI 1.01 to 1.25)
Intolerability: Low	1 RCT, N=148[13]	Low	Direct	Unknown	Imprecise	None	None	Intolerability (having an event where patient needed to reduce the dose or stop their antidepressant): Usual care=15% vs guided=4%; RR 1.13 (95% CI 1.01 to 1.25)
ABCB1 Genotyping								
Remission: Moderate	1 Observational N=116[15]	Medium	Direct	Unknown	Precise	Suspected (selective analysis reporting bias) (no report on harms/adverse events)	None	Improved remission (HAM-D<10): 83.6% vs 62.1%; X^2 (1)=6.596, P=0.005
GeneSight								
Remission: Low	1 RCT, N=51[14]	Medium	Direct	Unknown	Imprecise	None	None	No difference in remission (HAM-D ≤ 7): 20% vs 8%; RR 2.40 (95% CI 0.51 to 11.21)
Response	1 RCT, N=51[14]	Medium	Direct	Unknown	Imprecise	None	None	No difference in response (≥ 50% HAM-D improvement): 36% vs 21%; RR 2.14 (95% CI 0.56 to 7.69)

HAM-D=Hamilton Rating Scale for Depression; RR=Risk Ratio; OR=Odds Ratio